CD274 and non-small cell lung carcinoma: Study enrolled anti–PD-1/PD-L1-refractory NSCLC patients into vibostolimab (200 or 210 mg) monotherapy arm or the combination arm with the primary objective of evaluating safety and tolerability of vibostolimab when given alone or in combination with pembrolizumab.